Verastem traded at $5.82 this Friday February 13th, decreasing $0.02 or 0.34 percent since the previous trading session. Looking back, over the last four weeks, Verastem lost 14.29 percent. Over the last 12 months, its price fell by 2.51 percent. Looking ahead, we forecast Verastem to be priced at 5.64 by the end of this quarter and at 5.13 in one year, according to Trading Economics global macro models projections and analysts expectations.
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.